Contract development and manufacturing organisation: difference between revisions
Diff·revision 11 → 12·17:42, 12 Mar 2025
Difference between revision 11 and revision 12 of Contract development and manufacturing organisation. 6 lines changed; the page grew by 122 bytes.
| Revision 11 — 02:38, 25 Feb 2025 AnalyticalAnnie (talk) clarify that the cake appearance is an indicator, not a specification 3,462 bytes +587 | Revision 12 — 17:42, 12 Mar 2025 ResolutionRoo (talk) ce, tighten prose 3,584 bytes +122 | ||
|---|---|---|---|
| 36 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> | 36 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> |
| 37 | 37 | ||
| + | 38 | == See also == | |
| + | 39 | * [[Custom peptide synthesis]] | |
| + | 40 | * [[Good manufacturing practice]] | |
| + | 41 | * [[Lot traceability]] | |
| + | 42 | * [[Repackaging]] | |
| + | 43 | ||
| 38 | {{DEFAULTSORT:Contract development and manufacturing organisation}} | 44 | {{DEFAULTSORT:Contract development and manufacturing organisation}} |
| 39 | [[Category:Contract manufacturers]] | 45 | [[Category:Contract manufacturers]] |